The numbers don’t lie, GlaxoSmithKline plc is set to beat AstraZeneca plc this year

First quarter results from AstraZeneca plc (LON: AZN) and GlaxoSmithKline plc (LON: GSK) clearly show which is the better company.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) has made a great start to 2016. The company’s first-quarter results released at the end of last week, showed that Glaxo is on course to increase earnings by 10% to 12% this year, which is slightly ahead of market expectations.

During the first quarter, growth in HIV drugs, vaccines, and consumer healthcare helped offset a further decline in respiratory medicines while benefits of cost cuts and restructuring contributed to improving profit margins across the group. Overall sales increased by 11% to £6.23bn. Earnings per share excluding exceptional items and adjusted for currency rose 8% to 19.8p ahead of City forecasts which were calling for earnings per share of 18.2p. 

A fifth of pharma sales during the quarter came from new brands, putting the group on course for its target to reach £6bn of annual revenues from new products by 2018.

There’s no denying that these first quarter results from Glaxo are extremely encouraging. The group seems to be on track to hit its growth forecast for this year and a strong performance across all of the company’s divisions shows that management’s turnaround plan is working.

Struggling to gain traction 

On the other hand, it appears as if AstraZeneca’s (LSE: AZN) recovery is struggling to gain traction. The company’s first-quarter results showed that core profit fell in the first three months of the year, even as revenues rose. 

Higher research spending was to blame for the underlying drop in profitability. Research spending climbed 15% year-on-year to $1.4bn, core operating profit fell by 12% to $1.6bn and revenues increased by 1% to $6.13bn. 

On the face of it, these figures don’t seem too bad. However, Astra’s Q1 numbers were bolstered by some accounting factors, which helped the company boost its bottom line. 

For example, net profit for the period increased 17% to $646m as a result of lower amortisation charges. Also, the company received a huge boost from its so-called externalisation deals which raised $550m in proceeds during the first quarter, up from $309m a year earlier. Without this revenue boost, Astra would have reported a near 5% year-on-year decline in sales. Management expects total revenue and core earnings per share to decrease by a low-to-mid-single-digit percentage in 2016.

The bottom line 

All in all, the first quarter results from Glaxo and Astra tell two different stories. Glaxo’s turnaround is starting to gain traction as sales of the company’s new treatments pick up. But Astra is still struggling to report any real organic growth; the company is relying on externalisation revenues or one-off asset sales to improve its quarterly figures.

And if you’re looking for income, you can’t go wrong with Glaxo. The company’s shares currently support a dividend yield of 5.6% and trade at a forward P/E of 16.5. Astra’s shares support a yield of 5% and trade at a forward PE of 14.1.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A graph made of neon tubes in a room
Investing Articles

Up 262%! This lesser-known energy company is putting other S&P 500 stocks to shame

Our writer delves into the rationale behind the parabolic growth of this under-the-radar S&P 500 energy company. The reason isn’t…

Read more »

Investing Articles

Just released: December’s small-cap stock recommendation [PREMIUM PICKS]

We believe the UK small-cap market offers a myriad of opportunities across a wide range of different businesses and industries.

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

£20k of savings? Here’s how an investor could turn that into passive income of £5k a year

A £20k lump sum, invested in a mix of blue-chip shares with a long-term approach, could generate thousands of pounds…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Is the BP share price set for a 75% jump?

The highest analyst target for BP shares in 2025 is 75% above the current price. So should investors consider buying…

Read more »

UK money in a Jar on a background
Investing Articles

An investor could start investing with just £5 a day. Here’s how

Christopher Ruane explains how an investor could start investing in the stock market with limited funds, by following some simple…

Read more »

Solar panels fields on the green hills
Investing Articles

This renewable energy dividend stock offers a huge 13% yield

Dividend stocks focused on solar and other renewable energy sources are falling out of favour. It's time to take a…

Read more »

Investing Articles

Here’s why I’m expecting big things from my Stocks and Shares ISA in 2025!

Our writer explains why he believes his Stocks and Shares ISA is well positioned to deliver strong growth over the…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

When it comes to passive income, I think investors should listen to Warren Buffett’s advice about Olympic diving

When it comes to investing, Warren Buffett thinks it’s best to keep things simple. With Olympic diving, though, it’s a…

Read more »